Navigation Links
NeurogesX Reports First Quarter 2011 Results
Date:4/29/2011

grew to 60% of all institutional customers ordering in the first quarter 2011, up from 46% in fourth quarter 2010
  • The cumulative number of  private physician customers that have ordered Qutenza rose to 221 through March 31, 2011, up from 159 at December 31, 2010
  • Training activity continues with 1,535 physicians and institutions trained by March 31, 2011, up from 1,127 at December 31, 2010

  • First Quarter 2011 ResultsTotal revenue for the first quarter ended March 31, 2011 was $3.2 million, which consisted of $2.6 million in collaboration revenue, primarily from the amortization of upfront license fees received under the Astellas Agreement, and $0.6 million of Qutenza product sales.  

    During the three months ended March 31, 2011, the Company recorded sales of Qutenza to its specialty distribution and specialty pharmacy customers totaling $0.6 million. Under the Company's revenue recognition policy, the Company recognized revenue during the three months ended March 31, 2011 totaling $0.6 million.  

    Due to the limited history of product returns and cash collections, NeurogesX recognizes revenue at the later of the time the product is shipped by its customers to healthcare professionals and the date of cash collection.  As of March 31, 2011, the Company had $0.6 million of deferred product revenue.  Deferred revenue is reported net of associated cost of goods sold on the Company's balance sheet. Of the deferred revenue total, $0.4 million was sold through to end users (i.e., physicians, clinics and hospitals) and the deferral resulted from cash payments not yet being due under the payment terms, while $0.2 million represented deferral of sales into the Company's distribution channel, recognition of which will be based ultimately upon sales of those units to end users.

    Cost of goods sold for the first quarter 2011 totaled $0.1 million. Cost of goods sold includes product costs, fixed monthly cha
    '/>"/>

    SOURCE NeurogesX, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. NeurogesX Receives Notice of Allowance for Patent Covering NGX-1998 Capsaicin Topical Liquid
    2. NeurogesX Reports Fourth Quarter and Year-End 2010 Results
    3. NeurogesX to Provide Qutenza® Launch Update
    4. NeurogesX to Present at Two February Investor Conferences
    5. NeurogesX Receives Qutenza®-Specific J-Code From Centers for Medicare and Medicaid Services (CMS)
    6. NeurogesX Doses First Patient in Phase 2 Clinical Study of NGX-1998 Liquid Capsaicin Formulation
    7. NeurogesX to Hold Conference Call to Discuss Third Quarter 2010 Results
    8. NeurogesX to Present at Oppenheimer & Co Healthcare Conference
    9. Although NeurogesX/Astellass Qutenza is Only Approved for Postherpetic Neuralgia, Surveyed U.S. Physicians are Likely to Prescribe It for All Neuropathic Pain Types
    10. NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
    11. NeurogesX Receives FDA Approval of Qutenza(TM) (capsaicin) 8% Patch for Treatment of Postherpetic Neuralgia (PHN)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/23/2014)... 23, 2014  SI-BONE, Inc., a medical device company ... ® a minimally invasive surgical (MIS) device indicated ... that the U.S. Patent and Trademark Office has awarded ... for the fixation and fusion of bone.  This newly ... tapered distal end that may be placed from one bone across ...
    (Date:9/23/2014)... Sept. 23, 2014 Report Details ... you trends, R&D and predicted revenues Do you ... Now get the latest analysis for those cancer ... opportunities and revenue forecasts. Visiongain,s new report ... kinase inhibition and related technology. There avoid missing ...
    (Date:9/23/2014)... , Sept. 23, 2014 EnzymeBioSystems (OTCBB: ... along with the process of evaluating an enzyme ... in fighting tumors. In an effort to evaluate this ... with various contract research organizations to enlist their ... the use of an antitumor natural product called ...
    Breaking Medicine Technology:SI-BONE, Inc. Strengthens Patent Portfolio with the U.S. Patent and Trademark Office's Issuance of Threaded, Fenestrated Implant Method Patent 2SI-BONE, Inc. Strengthens Patent Portfolio with the U.S. Patent and Trademark Office's Issuance of Threaded, Fenestrated Implant Method Patent 3Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 2Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 3Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 4Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 5EnzymeBioSystems Announces Progress with an Enzyme Compound 2
    ... today reported financial results for the third quarter ended,September ... Novavax reported a net loss of $9.0 million, or ... $5.0 million net loss, or the,equivalent of $0.08 loss ... For the nine months ended September 30, 2007, the ...
    ... Allos,Therapeutics, Inc. (Nasdaq: ALTH ) today announced ... non-randomized, open-label, multi-center dose,escalation study of the Company,s ... tumors or non-Hodgkin,s lymphoma (NHL). "We are ... said Pablo,J. Cagnoni, M.D., Chief Medical Officer of ...
    Cached Medicine Technology:Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 2Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 3Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 4Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 5Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 6Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma 2Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma 3Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma 4
    (Date:9/23/2014)... TUESDAY, Sept. 23, 2014 (HealthDay News) -- A test used ... geographic regions where certain lung infections are more common, a ... lung cancer is through the use of what,s known as ... imaging called FDG-PET is used, according to the study authors. ... do parts of the lungs that don,t have ...
    (Date:9/23/2014)... Avid collector Andrew Hawley, from Vintage Rock Posters, ... Seattle concert posters. The Doors were a smash hit after ... The Seattle Eagles Auditorium concert was held on July 23. ... Eagles Auditorium in November the same year. The artist that ... in three colors. The poster is a split fountain silkscreen ...
    (Date:9/23/2014)... What: Rutgers Presbyterian Church, a ... that embodies the inclusion and diversity of New ... the Ecological Crisis, a public lecture led by ... of Old Testament at Louisville Presbyterian Seminary. Tull ... lends insight into current ecological problems, including energy ...
    (Date:9/23/2014)... A recent Oregon survey about an exercise DVD ... daily routine of elementary school students found it had ... teachers, and offered clear advantages for overly sedentary educational ... and produced by the Healthy Youth Program of the ... available nationally. , Brain Breaks leads children in 5-7 ...
    (Date:9/23/2014)... OAK BROOK, Ill. (September 23, 2014) Both ... malignancy with screening computed tomography (CT) colonography greatly ... invasive follow-up tests precipitated by false-positive diagnoses, according ... issue of the journal Radiology . , ... target a specific organ. However, when screening for ...
    Breaking Medicine News(10 mins):Health News:Lung Infections May Hamper Ability to Detect Lung Cancer 2Health News:Inhabiting Eden: Christians, Scripture, and the Ecological Crisis – Public Lecture to Discuss Faith-Based Environmentalism 2Health News:'Brain Breaks' increase activity, educational performance in elementary schools 2Health News:'Brain Breaks' increase activity, educational performance in elementary schools 3Health News:Patients accept false-positives to achieve diagnostic sensitivity 2Health News:Patients accept false-positives to achieve diagnostic sensitivity 3
    ... Completes Renovation of Local ... Pediatrician,s Office, HOUSTON, Dec. ... Office Makeover" for pediatrician Dr.,Muhammad Shaikh at the Bissonet Medical Center ... initiative that AMERIGROUP Community,Care sponsored for the area,s physicians and its ...
    ... Aida,Pharmaceuticals (OTC Bulletin Board: AIDA) today ... has been named as a "New and,High-Tech ... New High,Technology Service Centre ("SNHTSC"), a special ... Government. This,designation will allow Rh-Apo2L to have ...
    ... and Treat Alzheimer,s Disease, MORGANTOWN, W.Va., Dec. 4 ... discovered that,a cancer drug - Bryostatin - enhances the ... This drug could potentially increase,normal memory capacity in humans ... disease, stroke and head trauma., In an article ...
    ... Proceeds Benefit Institute on Aging and the Center for ... Elderly Suicide Prevention (CESP), SAN ... at San Francisco,s War Memorial Veterans Building Green,Room, the Center for ... on Aging (IOA), celebrates their 21st Annual,Cable Car Caroling fundraising event. ...
    ... Capital Through 2010, LOUISVILLE, Ky., Dec. 4 Almost Family, ... terms of its,previously existing $22.5 million bank credit facility., ... in borrowings with a maturity date of June 2010. -- ... Earnings Before Interest Taxes Depreciation and Amortization ...
    ... Pa., Dec. 4 The Capital BlueCross Medicare,Advantage ... Keystone,Health Plan Central, was ranked as the No. ... a report issued today by the Pennsylvania,Health Care ... Containment Council is an independent state agency formed ...
    Cached Medicine News:Health News:AMERIGROUP Community Care Provides 'Doctor's Office Makeover' in Houston 2Health News:Rh-Apo2L Named as One of China's High-Tech Transforming Products by Chinese Government 2Health News:Drug Found to Create New Connections in Brain, Restoring and Improving Memory 2Health News:Carolers Bring Holiday Cheer to Homebound Seniors 2Health News:Almost Family Announces Expansion of Revolving Credit Facility 2Health News:Almost Family Announces Expansion of Revolving Credit Facility 3Health News:Capital BlueCross HMO Plan is Ranked No. 1 in Pennsylvania for Member Satisfaction 2
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: